165 related articles for article (PubMed ID: 35797243)
1. HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition.
Moison C; Spinella JF; Chagraoui J; Lavallée VP; Lehnertz B; Thiollier C; Boivin I; Mayotte N; MacRae T; Marinier A; Hébert J; Sauvageau G
Blood Adv; 2022 Aug; 6(16):4793-4806. PubMed ID: 35797243
[TBL] [Abstract][Full Text] [Related]
2. G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress.
Didier C; Cavelier C; Quaranta M; Galcera MO; Demur C; Laurent G; Manenti S; Ducommun B
Oncogene; 2008 Jun; 27(27):3811-20. PubMed ID: 18212737
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation.
Bai J; Yokomizo-Nakano T; Kubota S; Sun Y; Kanai A; Iimori M; Harada H; Iwama A; Sashida G
Oncogene; 2021 Feb; 40(8):1531-1541. PubMed ID: 33452460
[TBL] [Abstract][Full Text] [Related]
4. Silencing of HMGA2 reverses retardance of cell differentiation in human myeloid leukaemia.
Tan L; Xu H; Chen G; Wei X; Yu B; Ye J; Xu L; Tan H
Br J Cancer; 2018 Feb; 118(3):405-415. PubMed ID: 29384529
[TBL] [Abstract][Full Text] [Related]
5. Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemia.
Terpstra W; Prins A; Ploemacher RE; Wognum BW; Wagemaker G; Löwenberg B; Wielenga JJ
Blood; 1996 Mar; 87(6):2187-94. PubMed ID: 8630378
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional repression of Cdc25B by IER5 inhibits the proliferation of leukemic progenitor cells through NF-YB and p300 in acute myeloid leukemia.
Nakamura S; Nagata Y; Tan L; Takemura T; Shibata K; Fujie M; Fujisawa S; Tanaka Y; Toda M; Makita R; Tsunekawa K; Yamada M; Yamaoka M; Yamashita J; Ohnishi K; Yamashita M
PLoS One; 2011; 6(11):e28011. PubMed ID: 22132193
[TBL] [Abstract][Full Text] [Related]
7. Amplified HMGA2 promotes cell growth by regulating Akt pathway in AML.
Tan L; Wei X; Zheng L; Zeng J; Liu H; Yang S; Tan H
J Cancer Res Clin Oncol; 2016 Feb; 142(2):389-99. PubMed ID: 26319392
[TBL] [Abstract][Full Text] [Related]
8. HMGA2 promotes long-term engraftment and myeloerythroid differentiation of human hematopoietic stem and progenitor cells.
Kumar P; Beck D; Galeev R; Thoms JAI; Talkhoncheh MS; de Jong I; Unnikrishnan A; Baudet A; Subramaniam A; Pimanda JE; Larsson J
Blood Adv; 2019 Feb; 3(4):681-691. PubMed ID: 30808686
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.
Banker DE; Groudine M; Willman CL; Norwood T; Appelbaum FR
Leuk Res; 1998 Mar; 22(3):221-39. PubMed ID: 9619914
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
[TBL] [Abstract][Full Text] [Related]
11. HMGA2 gene is a promising target for ovarian cancer silencing therapy.
Malek A; Bakhidze E; Noske A; Sers C; Aigner A; Schäfer R; Tchernitsa O
Int J Cancer; 2008 Jul; 123(2):348-356. PubMed ID: 18452175
[TBL] [Abstract][Full Text] [Related]
12. HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells.
Natarajan S; Hombach-Klonisch S; Dröge P; Klonisch T
Neoplasia; 2013 Mar; 15(3):263-80. PubMed ID: 23479505
[TBL] [Abstract][Full Text] [Related]
13. ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML.
Capala ME; Vellenga E; Schuringa JJ
PLoS One; 2014; 9(10):e111568. PubMed ID: 25360637
[TBL] [Abstract][Full Text] [Related]
14. Live kinase B1 maintains CD34
Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C
Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012
[TBL] [Abstract][Full Text] [Related]
15. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia.
Lewis NR; Pallis M; Russell NH
Exp Hematol; 2000 May; 28(5):535-42. PubMed ID: 10812243
[TBL] [Abstract][Full Text] [Related]
16. HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/β-catenin signaling.
Yang S; Gu Y; Wang G; Hu Q; Chen S; Wang Y; Zhao M
Int J Mol Med; 2019 Aug; 44(2):427-436. PubMed ID: 31173171
[TBL] [Abstract][Full Text] [Related]
17. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
[TBL] [Abstract][Full Text] [Related]
18. Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance.
Karantanos T; Jones RJ
Adv Exp Med Biol; 2019; 1139():153-169. PubMed ID: 31134500
[TBL] [Abstract][Full Text] [Related]
19. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
Kang LC; Dunphy CH
Arch Pathol Lab Med; 2006 Feb; 130(2):153-7. PubMed ID: 16454553
[TBL] [Abstract][Full Text] [Related]
20. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia.
Bernstein ID; Singer JW; Smith FO; Andrews RG; Flowers DA; Petersens J; Steinmann L; Najfeld V; Savage D; Fruchtman S
Blood; 1992 Apr; 79(7):1811-6. PubMed ID: 1373089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
